Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era
- Conditions
- Patient's Outcome Prognostic Factors
- Registration Number
- NCT03663894
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Introduction High dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT) is a therapeutic option in follicular Lymphoma after first line treatment failure. The clinical characteristics and outcome of FL patients who relapsed after HDT+ASCT and therapeutic management in the rituximab era are not well known and may represent a difficult challenge.
Patients and Methods: The investigators conducted a retrospective analysis of FL patients who relapsed after HDT+ASCT in four French centers treated between 2000 and 2014. Clinical records were reviewed for clinical characteristics and treatment strategy at relapse. The investigators aimed to identify prognostic factors related to patient's outcome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 95
- they were older than 18 years
- presented FL at diagnosis (Grade 1, 2, or 3a).
- received high-dose therapy (HDT) with ASCT from 2000 to 2014
- they had already been treated with a 1st ASCT,
- had a previous history of histological transformation before ASCT
- if they were rituximab naive prior to ASCT.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival after relapse (SAR) post ASCT in follicular lymphoma Year 6 Factors that predicted SAR
- Secondary Outcome Measures
Name Time Method Histological Transformation at relapse Year 6 A biopsy was performed at the first relapse or progression after ASCT.
treatment of relapse Year 6 Chemotherapy, radiotherapy...
Trial Locations
- Locations (1)
Centre Hospitalier Lyon Sud, Hematology department
🇫🇷Pierre-Bénite, France